Sofocure-L is a combination antiviral medication containing Sofosbuvir (400 mg) and Ledipasvir (90 mg), used for the treatment of chronic hepatitis C virus (HCV) infection. It is specifically effective against HCV genotype 1, 4, 5, and 6 and is known for its high cure rates exceeding 95% when taken as prescribed.
Sofosbuvir is a nucleotide polymerase inhibitor, while Ledipasvir is an NS5A inhibitor. Together, they block viral replication and reduce the HCV viral load, ultimately leading to complete viral clearance from the body. The standard dosage is one tablet per day, taken orally, with or without food, for 12 to 24 weeks, depending on the patient’s liver condition and prior treatment history.
Common side effects of Sofocure-L include fatigue, headache, nausea, diarrhea, and insomnia. In rare cases, it may cause severe liver complications or bradycardia (slow heart rate), particularly when taken with amiodarone. Patients with advanced liver disease or those taking other medications should consult their doctor before starting treatment.
Sofocure-L is a highly effective and well-tolerated option for treating HCV, offering hope for patients seeking a cure. Regular monitoring through liver function tests (LFTs) is essential to ensure safety and treatment success.
Reviews
There are no reviews yet.